Frédéric Calon

Research Interests:
Medicine, Clinical Sciences, and Neurosciences

Download (.pdf)

Publication Date: 2014

Publication Name: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)

Research Interests:
Cognition, Learning, Memory, Brain, Pregnancy, and 12 moreHumans, Child, Female, Animals, Male, Infant, Dietary Supplements, Clinical Sciences, Adult, Fetus, Alzheimer Disease, and Biochemistry and cell biology

Download (.pdf)

Publication Date: 2008

Research Interests:
Psychology, Animal Behavior, Quality of life, Neuropharmacology, Motor Control, and 16 moreImmunohistochemistry, Caudate Nucleus, Low Dose, Female, Animals, Ligand Binding, Rat Brain, Levodopa, Amino Acids, Globus Pallidus, Basal ganglia, Autoradiography, Macaca fascicularis, Putamen, Neurosciences, and Ovariectomy

Download (.pdf)

Transactive response DNA binding protein 43 (TDP-43) plays a central role in the neuropathology of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, but the relationship between TDP-43 abnormalities and Alzheimer... more

Transactive response DNA binding protein 43 (TDP-43) plays a central role in the neuropathology of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, but the relationship between TDP-43 abnormalities and Alzheimer disease (AD) remains unclear. To determine whether TDP-43 can serve as a neuropathologic marker of AD, we performed biochemical characterization and quantification of TDP-43 in homogenates from parietal neocortex of subjects with aclinical diagnosis of no cognitive impairment (NCI, n = 12), mild cognitive impairment (MCI, n = 12), or AD (n = 12). Immunoblots revealed increased detergent-insoluble TDP-43 in the cortex of 0, 3, and 6 of the 12 individuals with NCI, MCI, or AD, respectively. Detergent-insoluble TDP-43 was positively correlated with the accumulation of soluble Aβ42, amyloid plaques, and paired helical filamenttau. In contrast, phospho-TDP-43 was decreased in the cytosolic fraction and detergent-soluble membrane/nuclear fraction from AD patien...

Publication Name: Journal of Neuropathology and Experimental Neurology

Research Interests:
Brain, Humans, Female, Male, Clinical Sciences, and 7 moreAged, Analysis of Variance, Alzheimer Disease, DNA binding proteins, Neurosciences, Enzyme Linked Immunosorbent Assay, and Cognition disorders

Download (.pdf)

02bfe513106ca13fd8000000.pdf20160115-19908-1627ow8.pdf

02bfe513106ca13fd8000000.pdf20160115-19908-i82x4m.pdf

Publication Name: Alzheimer's and Dementia

Research Interests:
Clinical Sciences and Neurosciences

Dietary supplementation with n-3 polyunsaturated fatty acids (n-3 PUFA) reduces amyloid-β (Aβ) and tau pathology and improves cognitive performance in animal models of Alzheimer's disease (AD). To exclude confounding variables... more

Dietary supplementation with n-3 polyunsaturated fatty acids (n-3 PUFA) reduces amyloid-β (Aβ) and tau pathology and improves cognitive performance in animal models of Alzheimer's disease (AD). To exclude confounding variables associated with the diet, we crossed 3 × Tg-AD mice (modeling AD neuropathology) with transgenic Fat-1 mice that express the fat-1 gene encoding a PUFA desaturase, which endogenously produces n-3 PUFA from n-6 PUFA. The expression of fat-1 shifted the n-3:n-6 PUFA ratio upward in the brain (+11%, p < 0.001), including docosahexaenoic acid (DHA; +5%, p < 0.001) in 20 month-old mice. The expression of fat-1 decreased the levels of soluble Aβ₄₂ (-41%, p < 0.01) at 20 months without reducing the level of insoluble forms of Aβ₄₀ and Aβ₄₂ in the brain of 3 × Tg-AD mice. The 3 × Tg-AD/Fat-1 mice exhibited lower cortical levels of both soluble (-25%, p < 0.05) and insoluble phosphorylated tau (-55%, p < 0.05) compared to 3 × Tg-AD mice, but only in ...

Publication Date: 2011

Publication Name: Journal of Alzheimer's disease : JAD

Research Interests:
Cognitive Science, Signal Transduction, Brain, Humans, Mutation, and 12 moreMice, Omega-3 fatty acids, Animals, Phosphorylation, Clinical Sciences, Analysis of Variance, Presenilin-2, Alzheimer Disease, Neurosciences, Enzyme Linked Immunosorbent Assay, Gene Expression Regulation, and Amyloid Beta Precursor Protein

Download (.pdf)

The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal lesion and dopaminomimetic treatment on parameters of glutamatergic activity within the basal ganglia of monkeys were studied in relation with the... more

The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal lesion and dopaminomimetic treatment on parameters of glutamatergic activity within the basal ganglia of monkeys were studied in relation with the development of dyskinesias. Drug-naive controls, saline-treated MPTP monkeys, as well as MPTP monkeys treated with either a long-acting D2 agonist (cabergoline) or a D1 agonist (SKF-82958) given by intermittent injections or continuous infusion, were included in this study. 3H-L-glutamate, 3H-alpha-amino-3-hydroxy-5-methylisoxasole-4-propionate (AMPA), 3H-glycine, 3H-CGP39653 (an N-methyl-D-aspartate, NMDA, antagonist selective for NR1/NR2A assembly) and 3H-Ro 25-6981 (an NMDA antagonist selective for NR1/NR2B assembly), specific binding to glutamate receptors, the expression of the NR1 subunit of NMDA receptors and glutamate, glutamine and glycine concentrations were studied by autoradiography, in situ hybridization and high-performance liquid chroma...

Publication Date: 2002

Publication Name: Progress in neuro-psychopharmacology & biological psychiatry

Research Interests:
Glutamate, Glutamate receptors, Female, Animals, High Performance Liquid Chromatography, and 11 moremRna expression levels, Glutamine, Liquid Chromatography, Basal ganglia, Macaca fascicularis, Amino Acid Profile, Glycine, Reference Values, Glutamic Acid, Glutamate Receptor, and Ovariectomy

Download ()

For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications... more

For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications occurring in most parkinsonian patients. Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or a glutamate NMDA NR2B-selective antagonist (CI-1041), have afforded protection against dyskinesia, perhaps through presynaptic inhibition of glutamate release and blockade of supersensitive postsynaptic NMDA receptors in the striatum, respectively. Some of the biochemical events that have correlated with dyskinesias, namely upregulated GABA(A) receptors in the internal pallidum, rise in pre-proenkephalin-A gene expression in the striatum, and upregulated striatal glutamate ionotropic receptors and adenosine A(2a) receptors, may be counteracted by these preventive strategies.

Publication Date: 2004

Research Interests:
Cognitive Science, Gene expression, Glutamate, Humans, Animals, and 2 morePresynaptic Inhibition and Clinical Sciences

Research Interests:
Neurology, Dopamine, Brain, Humans, Animals, and 6 moreDopamine Receptors, Levodopa, Clinical Sciences, Neural pathways, Neurosciences, and Parkinson Disease

Publication Date: 2009

Publication Name: Neuropharmacology

Research Interests:
Psychology, Neuropharmacology, Immunohistochemistry, Brain, Humans, and 16 moreGlucose, Basement Membrane, Mice, Blood brain barrier, Animals, Frontal Cortex, Mouse Model, Functional integration, Blood Vessels, Diazepam, Brain Chemistry, Transgenic Mouse Technology, Alzheimer Disease, Collagen Type IV, Brain Perfusion, and Neurosciences

Download (.pdf)

Publication Date: 2000

Publication Name: Trends in Neurosciences

Research Interests:
Cognitive Science, Gene expression, Signal Transduction, Neuropeptides, TRENDS, and 9 moreGlutamate receptors, GABA receptors, Animals, dopamine receptor D4, Dopamine Receptors, Levodopa, Basal ganglia, Neurosciences, and Mono

Download ()

Publication Date: 2014

Publication Name: Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)

Research Interests:
Cognition, Learning, Memory, Brain, Pregnancy, and 12 moreHumans, Child, Female, Animals, Male, Infant, Dietary Supplements, Clinical Sciences, Adult, Fetus, Alzheimer Disease, and Biochemistry and cell biology

Download (.pdf)

Publication Date: 2002

Publication Name: Progress in Neuro-Psychopharmacology and Biological Psychiatry

Research Interests:
Glutamate, Glutamate receptors, Female, Animals, High Performance Liquid Chromatography, and 11 moremRna expression levels, Glutamine, Liquid Chromatography, Basal ganglia, Macaca fascicularis, Amino Acid Profile, Glycine, Reference Values, Glutamic Acid, Glutamate Receptor, and Ovariectomy

Download ()

Publication Date: 2014

Publication Name: PLoS ONE

Research Interests:
Multidisciplinary, Humans, Mutation, Mice, Animals, and 6 moreMonoclonal Antibodies, Phosphorylation, Artifacts, PLoS one, Amino Acid Sequence, and Alzheimer Disease

Download (.pdf)

Publication Date: 2011

Publication Name: PLoS ONE

Research Interests:
Multidisciplinary, Neurodegenerative Diseases, Humans, Mice, Animals, and 12 moreNeurons, Human Brain, PLoS one, Enzyme, Mouse Model, Primary Culture, Alzheimer Disease, Cell Survival, Docosahexaenoic Acid, Gene Expression Regulation, Neuroprotective Agents, and Amyloid Beta Precursor Protein

Download (.pdf)

For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications... more

For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications occurring in most parkinsonian patients. Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or a glutamate NMDA NR2B-selective antagonist (CI-1041), have afforded protection against dyskinesia, perhaps through presynaptic inhibition of glutamate release and blockade of supersensitive postsynaptic NMDA receptors in the striatum, respectively. Some of the biochemical events that have correlated with dyskinesias, namely upregulated GABA(A) receptors in the internal pallidum, rise in pre-proenkephalin-A gene expression in the striatum, and upregulated striatal glutamate ionotropic receptors and adenosine A(2a) receptors, may be counteracted by these preventive strategies.